Hypotension associated with intravitreal bevacizumab therapy for retinopathy of prematurity

Lu Hsuan Wu, Yea Huei Kao Yang, Chyi Her Lin, Yuh Jyh Lin, Ching Lan Cheng

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Intravitreal bevacizumab therapy in preterm infants for retinopathy of prematurity (ROP) can be associated with hypotension. We report twin preterm infants who developed hypotension within 1 day after intravitreal bevacizumab therapy for ROP. Before receiving the medication, their clinical statuses were stable and similar. The dose, procedure, and premedication were the same; however, twin B presented with hypotension for 3 days. Although bevacizumab-related hypotension has been described in product information (incidence rate 7%-15%), this is the first case report of intravitreal bevacizumab for ROP inducing hypotension. Physicians should be aware of intravitreal bevacizumab therapy-related hypotension when treating ROP. We suggest conducting a postmarketing active surveillance on the systemic adverse effects of this regimen in preterm infants.

Original languageEnglish
Article numbere20152005
JournalPediatrics
Volume137
Issue number2
DOIs
Publication statusPublished - 2016 Feb

Fingerprint

Retinopathy of Prematurity
Hypotension
Premature Infants
Therapeutics
Premedication
Bevacizumab
Physicians
Incidence

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

@article{2ae5a13c8d23440b8bad65c462990030,
title = "Hypotension associated with intravitreal bevacizumab therapy for retinopathy of prematurity",
abstract = "Intravitreal bevacizumab therapy in preterm infants for retinopathy of prematurity (ROP) can be associated with hypotension. We report twin preterm infants who developed hypotension within 1 day after intravitreal bevacizumab therapy for ROP. Before receiving the medication, their clinical statuses were stable and similar. The dose, procedure, and premedication were the same; however, twin B presented with hypotension for 3 days. Although bevacizumab-related hypotension has been described in product information (incidence rate 7{\%}-15{\%}), this is the first case report of intravitreal bevacizumab for ROP inducing hypotension. Physicians should be aware of intravitreal bevacizumab therapy-related hypotension when treating ROP. We suggest conducting a postmarketing active surveillance on the systemic adverse effects of this regimen in preterm infants.",
author = "Wu, {Lu Hsuan} and Yang, {Yea Huei Kao} and Lin, {Chyi Her} and Lin, {Yuh Jyh} and Cheng, {Ching Lan}",
year = "2016",
month = "2",
doi = "10.1542/peds.2015-2005",
language = "English",
volume = "137",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "2",

}

Hypotension associated with intravitreal bevacizumab therapy for retinopathy of prematurity. / Wu, Lu Hsuan; Yang, Yea Huei Kao; Lin, Chyi Her; Lin, Yuh Jyh; Cheng, Ching Lan.

In: Pediatrics, Vol. 137, No. 2, e20152005, 02.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hypotension associated with intravitreal bevacizumab therapy for retinopathy of prematurity

AU - Wu, Lu Hsuan

AU - Yang, Yea Huei Kao

AU - Lin, Chyi Her

AU - Lin, Yuh Jyh

AU - Cheng, Ching Lan

PY - 2016/2

Y1 - 2016/2

N2 - Intravitreal bevacizumab therapy in preterm infants for retinopathy of prematurity (ROP) can be associated with hypotension. We report twin preterm infants who developed hypotension within 1 day after intravitreal bevacizumab therapy for ROP. Before receiving the medication, their clinical statuses were stable and similar. The dose, procedure, and premedication were the same; however, twin B presented with hypotension for 3 days. Although bevacizumab-related hypotension has been described in product information (incidence rate 7%-15%), this is the first case report of intravitreal bevacizumab for ROP inducing hypotension. Physicians should be aware of intravitreal bevacizumab therapy-related hypotension when treating ROP. We suggest conducting a postmarketing active surveillance on the systemic adverse effects of this regimen in preterm infants.

AB - Intravitreal bevacizumab therapy in preterm infants for retinopathy of prematurity (ROP) can be associated with hypotension. We report twin preterm infants who developed hypotension within 1 day after intravitreal bevacizumab therapy for ROP. Before receiving the medication, their clinical statuses were stable and similar. The dose, procedure, and premedication were the same; however, twin B presented with hypotension for 3 days. Although bevacizumab-related hypotension has been described in product information (incidence rate 7%-15%), this is the first case report of intravitreal bevacizumab for ROP inducing hypotension. Physicians should be aware of intravitreal bevacizumab therapy-related hypotension when treating ROP. We suggest conducting a postmarketing active surveillance on the systemic adverse effects of this regimen in preterm infants.

UR - http://www.scopus.com/inward/record.url?scp=84958725836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958725836&partnerID=8YFLogxK

U2 - 10.1542/peds.2015-2005

DO - 10.1542/peds.2015-2005

M3 - Article

C2 - 26743817

AN - SCOPUS:84958725836

VL - 137

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 2

M1 - e20152005

ER -